• Ironwood Pharmaceuticals Inc., of Cambridge, Mass., said the underwriters of its previously announced public stock offering fully exercised their option to purchase an additional 787,500 shares at a public offering price of $15.09 per share. Including the overallotment, Ironwood sold 6.0375 million shares at $15.09 each for gross proceeds of $91.1 million and estimated net proceeds of $85.3 million. Proceeds will support launch preparations for linaclotide, which is under FDA review for irritable bowel syndrome and chronic constipation.